氯吡格雷联合注射用尤瑞克林对急性脑梗死患者血浆超敏C反应蛋白和溶血磷脂酸的影响

目的观察氯吡格雷联合注射用尤瑞克林对急性脑梗死患者血浆超敏C反应蛋白(hs-CRP)和溶血磷脂酸(LPA)表达的影响。方法将90例急性脑梗死患者随机分为治疗组50例和对照组40例。对照组采用常规治疗,治疗组在常规治疗基础上加用氯吡格雷联合注射用尤瑞克林治疗,连续治疗14d。观察2组临床疗效及治疗前后NIHSS评分、日常生活活动能力(ADL)评分、hs-cRP及LPA水平。结果治疗组总有效率为96.0%高于对照组的82.5%,差异有统计学意义(P<0.05)。2组治疗后NIHSS和ADL评分均较治疗前明显改善,且治疗组改善程度优于对照组(P<0.05)。2组治疗后hs-CRP、LPA水平均较治疗前降低,且治疗组较对照组降低更明显,差异均有统计学意义(P<0.05)。结论氯吡格雷联合注射用尤瑞克林治疗急性脑梗死,可通过减少患者hs-CRP和LPA的表达而改善病情。

Effect of clopidogrel combined with urinary kallidinogenase injection on high sensitivity C-reactive protein and lysophosphatidic acid in patient with acute cerebral infarction

Objective To study the effect of clopidogrel combined with urinary kallidinogenase injection on high sensitivity C-reactive protein （hs-CRP） and lysophosphatidic acid （LPA） in patient with acute cerebral infarction. Methods 90 cases patients with acute cerebral infarction were randomly divided into treatment group （50 cases） and control group （40 cases）. Control group was treated with the conventional treatment ,while the treatment group were cured with clopidogrel combined with urinary kallidinogenase injection on the basis of the conventional treatment. They were treated for 14 days. Observed the clinical effect of two groups ; NIHSS score, ADL score, hs-CRP and LPA levels were compared before and after the treatment. Results The total effective rate of treatment group （96.0%） was higher than that of control group （82.5 % ）, the difference was statisti- cally significant（ P 〈 0.05 ）. The scores of NIHSS and ADL of two groups were improved after treatment, but the treatment group were better than control group ;The hs-CRP and LPA levels of two groups were decreased after treatment, but the treat- ment groups were more significantly decreased than control group ,the difference were statistically significant（ P 〈 0.05 ）. Conclusion The treatment of clopidogrel combined with urinary kallidinogenase injection can improve the stations of patients with acute cerebral infarction, which is through decreasing hs-CRP and LPA level.